Clinical Trial Update: Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 clinical trial evaluating donor-virus-specific CMV- and AdV-directed cytotoxic T lymphocytes to prevent or treat CMV or adenovirus reactivation or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoviral Infection
• Cytomegalovirus Infection

Drugs mentioned

• Donor-virus-specific CMV/AdV cytotoxic T lymphocytes (donor-derived CMV- and adenovirus-specific cytotoxic T lymphocytes)

Snippet

Sponsor: Sumithira Vasu | Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus | EARLY_Phase 1 | Status: RECRUITING